<DOC>
	<DOCNO>NCT00701701</DOCNO>
	<brief_summary>An exploratory , open-labeled study patient Pompe disease , previously receive Myozyme ( alglucosidase alfa ) treatment , evaluate efficacy , safety clinical benefit 2 Immune Tolerance Induction ( ITI ) regimens combination Myozyme . Eligible patient currently receive Myozyme therapy enrol study , follow minimum 18 month on-study ( 6-month ITI treatment module 12-month follow-up module Myozyme alone ) . Eligible patient follow minimum 18 month treatment , patient &lt; 6 month age time enrollment , patient 2 year age . Both cross-reacting immunologic material ( CRIM ) -negative CRIM-positive patient eligible Regimen A depend meet required criterion . Regimen B however , limited CRIM-negative patient .</brief_summary>
	<brief_title>Immune Tolerance Induction Study</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>The patient ( and/or patient 's legal guardian patient &lt; 18years ) must provide write informed consent prior studyrelated procedure perform ; The patient must confirm diagnosis Pompe disease define documented acid αglucosidase ( GAA ) enzyme deficiency tissue source 2 GAA gene mutation ; The patient ( and/or legal guardian ) must ability comply clinical protocol ; If patient Crossreacting immunologic material ( CRIM ) positive , he/she must receive least 6 consecutive month Myozyme infusion ( 20mg/kg qow ) If patient CRIMnegative , he/she must receive least 1 Myozyme infusion prior enrollment Regimen A : The patient exhibit clinical decline ; The patient persistent high antirecombinant human acid αglucosidase ( antirhGAA ) antibody titer and/or test positive antibody inhibit enzymatic activity and/or uptake Myozyme ; Regimen B : The patient CRIMnegative AND The patient exhibit clinical decline ; OR ALL OF THE FOLLOWING : The patient CRIMnegative AND The patient exhibit clinical decline AND The patient NOT exhibit high antirhGAA antibody titer NOT test positive antibody inhibit enzymatic activity and/or uptake Myozyme . The patient clinical condition unrelated Pompe disease would interfere program assessment ; The patient risk reactivation carrier Hepatitis B Hepatitis C ; The patient risk reactivation positive serology suggestive active infection cytomegalovirus , Herpes simplex , JC virus , Parvovirus Epstein Barr virus ; The patient risk reactivation tuberculosis regular contact individual actively treat tuberculosis ; The patient low serum albumin ; The patient major congenital abnormality ; The patient use investigational product ( alglucosidase alfa ) within 30 day prior study enrollment ; The patient pregnant lactating ; The patient require live vaccination within one month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>